EIM
HBIO icon

Essex Investment Management’s Harvard Bioscience HBIO Stock Holding History

Essex Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Buy
27,021
+8,553
+46% +$47.8K 0.02% 223
2025
Q4 		$124K Buy
+18,468
New +$110K 0.02% 226
2022
Q2 		– Sell
-43,185
Closed -$2.68M – 431
2022
Q1 		$2.68M Buy
43,185
+1,997
+5% +$118K 0.33% 89
2021
Q4 		$2.9M Buy
41,188
+3,114
+8% +$221K 0.33% 93
2021
Q3 		$2.66M Sell
38,074
-244
-0.6% -$19.4K 0.33% 95
2021
Q2 		$3.19M Buy
38,318
+8,266
+28% +$585K 0.37% 91
2021
Q1 		$1.64M Sell
30,052
-3,160
-10% -$154K 0.2% 172
2020
Q4 		$1.43M Sell
33,212
-6,237
-16% -$233K 0.18% 181
2020
Q3 		$1.19M Buy
39,449
+14,565
+59% +$490K 0.17% 189
2020
Q2 		$771K Sell
24,884
-116
-0.5% -$3.13K 0.13% 217
2020
Q1 		$553K Sell
25,000
-27,426
-52% -$743K 0.11% 210
2019
Q4 		$1.6M Buy
52,426
+2,464
+5% +$70.9K 0.2% 173
2019
Q3 		$1.54M Sell
49,962
-5,727
-10% -$142K 0.22% 148
2019
Q2 		$1.11M Buy
55,689
+8,060
+17% +$236K 0.15% 208
2019
Q1 		$2.05M Sell
47,629
-1,315
-3% -$47.7K 0.3% 97
2018
Q4 		$1.56M Sell
48,944
-3,243
-6% -$128K 0.24% 129
2018
Q3 		$2.74M Buy
52,187
+2,133
+4% +$120K 0.32% 88
2018
Q2 		$2.68M Buy
50,054
+61
+0.1% +$3.13K 0.34% 90
2018
Q1 		$2.5M Sell
49,993
-3,675
-7% -$165K 0.33% 91
2017
Q4 		$1.77M Sell
53,668
-414
-0.8% -$14K 0.23% 131
2017
Q3 		$2.03M Buy
54,082
+11,136
+26% +$329K 0.28% 117
2017
Q2 		$1.09M Buy
42,946
+11,988
+39% +$297K 0.16% 186
2017
Q1 		$805K Buy
30,958
+7,105
+30% +$205K 0.13% 215
2016
Q4 		$728K Buy
23,853
+8,002
+50% +$204K 0.12% 201
2016
Q3 		$431K Sell
15,851
-370
-2% -$10.3K 0.07% 269
2016
Q2 		$464K Sell
16,221
-179
-1% -$5.69K 0.08% 245
2016
Q1 		$495K Sell
16,400
-2,161
-12% -$61.3K 0.08% 229
2015
Q4 		$644K Sell
18,561
-1,240
-6% -$42.4K 0.1% 210
2015
Q3 		$748K Buy
+19,801
New +$921K 0.12% 173

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Essex Investment Management's HBIO Position: Q1 2026 in Review

Essex Investment Management increased its Harvard Bioscience (HBIO) stake by 46% in Q1 2026, buying an estimated $47.8K and bringing the position to 27,021 shares worth $132K. The position accounts for 0.02% of the portfolio, ranked #223.

Essex Investment Management first reported a position in HBIO in Q3 2015 and has held it in 29 quarters since. The position peaked at $3.19M in Q2 2021. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Essex Investment Management held 27,021 shares of Harvard Bioscience worth $132K as of Q1 2026.
  • Essex Investment Management bought 8,553 Harvard Bioscience shares in Q1 2026, an estimated $47.8K.
  • Harvard Bioscience made up 0.02% of Essex Investment Management's portfolio in Q1 2026, its #223 holding.
  • Essex Investment Management first reported a position in Harvard Bioscience in Q3 2015 and has held it in 29 quarters since.
  • Essex Investment Management's Harvard Bioscience position peaked at $3.19M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.